Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alrizomadlin - Ascentage Pharma

Next Previous
Drug Profile

Alrizomadlin - Ascentage Pharma

Alternative Names: APG-115

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Developer Ascentage Pharma; Suzhou Yasheng Pharmaceutical; University of Michigan
  • Class Amides; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Retinoblastoma; Gastric cancer; Acute myeloid leukaemia; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours; T-cell prolymphocytic leukaemia
  • Phase I/II Acute myeloid leukaemia; Liposarcoma; Salivary gland cancer
  • Phase I Neuroblastoma
  • Preclinical Multiple myeloma; Uveal melanoma
  • No development reported Dry age-related macular degeneration; Gastric cancer; Lymphoma; Myelodysplastic syndromes

Most Recent Events

  • 02 Jun 2025 Adverse events and efficacy data from a phase-I/II trial in Solid tumours (Monotherapy, Second-line therapy or greater, Combination therapy) released by Ascentage Pharma
  • 28 May 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in China (PO)
  • 28 May 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater, Chemotherapy-induced) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top